Article focus

The aim of this study was to assess osteochondral defect repair and articular cartilage regeneration in a canine model.

Autologous bone marrow derived mesenchymal stem cells were seeded onto platelet rich fibrin.

Macroscopic and histological assessments of the repair tissue were assessed for the treated and control defects at various time points.

Key messages

Higher cumulative macroscopic and histological scores were observed in treated defects.

We determined the feasibility of using this novel technique in osteochondral defect repair and articular cartilage regeneration.

Strengths and limitations

To our knowledge, this is the first study to report the combined use of stem cells and platelet rich fibrin in cartilage repair.
Lack of biomechanical and immunohistochemical assessments.
Lack of comparative assessment between active treatment groups.

Introduction
Successful treatment of articular cartilage injuries remains a major challenge for orthopaedic clinicians, with untreated lesions ultimately leading to osteoarthritis and degenerative joint disease. Articular cartilage is devoid of blood vessels, nerves and lymphatics and contains a minimum number of cells in the form of chondrocytes. Due to these structural characteristics, this highly specialised form of connective tissue has a very limited capacity for self-repair following injury. Among the various techniques of articular cartilage repair, cell-based therapies have emerged as an important means of treating focal cartilage lesions. Autologous chondrocyte implantation (ACI) is a form of cell therapy which is currently considered as the mainstay for regeneration of articular cartilage. During ACI, healthy chondrocytes are first harvested from a non-weight-bearing area of the joint and then transplanted back into cartilage lesions following in vitro isolation and culture expansion.1,6

Although the results of ACI treatment have been encouraging indicating the formation of hyaline like tissue,1,5,6 obtaining chondrocytes in sufficiently high cell densities and maintenance of their differentiation state is technically difficult.2,3,7 Hence, alternative cell sources are sought to replace chondrocytes. Currently, mesenchymal stem cells (MSCs) are considered as the potential replacements to chondrocytes in cell-based therapies. MSCs can easily be isolated, and culture expanded in sufficient numbers. They have also shown the ability to differentiate into various cell types, including chondrocytes, under laboratory conditions.1,5 Studies concerning the application of MSCs in cartilage repair have mainly focused on the use of bone marrow derived MSCs (BM-MSCs) and it has been shown that chondrogenic differentiation of these cells is induced by growth factors, in particular the transforming growth factor β (TGF-β) family.8,10 Wakitani et al11 were the first to demonstrate the efficacy of BM-MSCs in cartilage repair. Subsequently, numerous pre-clinical and clinical studies have documented the positive influence of BM-MSCs in articular cartilage repair and regeneration as reviewed by Bornes et al.12 Seeding of MSCs onto various types of scaffolds and the placement of these cell-laden structures inside cartilage lesions is a method employed for the delivery and implantation of MSCs into cartilage defects. Aside from containment of implanted MSCs inside cartilage lesions, the ideal scaffold should provide the bioactive molecules necessary for promotion of cellular differentiation and maturation.13 Growth factors are among the bioactive molecules that can induce chondrogenic differentiation of MSCs.14

Platelet-rich fibrin (PRF) is a platelet concentrate containing a multitude of growth factors including TGF-β.15,16 In vitro studies have indicated that PRF has the ability to support the proliferation of MSCs and various other cell types.17-20 PRF consists of a three-dimensional fibrin network favouring cytokine enmeshment and cellular migration. Its growth factors are slowly released over an extended period of time, making this biomaterial an attractive choice to be used as scaffold for the delivery of stem cells in tissue regeneration.21 Combination of MSCs and PRF has been used for dental, myocardial and bone regeneration and adipose tissue transplantation.21-28 Although it has been shown that PRF alone positively influences cartilage repair,29 the effect of MSCs combined with PRF on cartilage repair have not previously been studied.

The aim of the present study was to evaluate the effect of BM-MSCs seeded onto PRF for articular cartilage regeneration in a canine model. It was hypothesised that the combined use of MSCs and a biological source of growth factors in the form of PRF would enhance osteochondral repair and cartilage regeneration in comparison with untreated control defects.

Materials and Methods
Animals and study design. This experimental study was approved by the research council and experimentation ethics committee of our institution (research project number 2-17-5-16154 approved on 30.6.2012). All the experiments were conducted with adherence to institutional guidelines for the care and use of laboratory animals in research.

A total of 12 clinically healthy adult mixed breed male dogs with a body weight of between 18 kg and 40 kg were used in this study. They were judged to be healthy based on physical examination findings and results of laboratory tests (complete blood cell count, blood biochemistry profiles and urinalysis). The stifle joint of each animal was carefully examined to rule out any joint instability. Skeletal maturity was determined by radiography prior to the initiation of the experiment.

A total of 24 osteochondral defects were created on the medial femoral condyles of the stifle joint (two defects per dog, one on each limb). The stifle joint is the homologue for the human knee joint. In each dog, the defects were randomly treated by implantation of BM-MSCs seeded onto PRF or left empty as a control. Simple randomisation by flipping a coin was used to determine whether to treat the left (heads) or right (tails) stifle defect. The animals were killed at four, 16 and 24 weeks following creation of the defects, and the resultant repair tissue was evaluated by macroscopic and histological means.

Isolation, expansion and characterisation of BM-MSCs. Autologous BM-MSCs were isolated from the animals and culture expanded for later use according to the established
The animals were pre-medicated with 0.05 mg/kg of intramuscular acepromazine and anaesthesia was induced intravenously 15 to 20 minutes later with 10 mg/kg thiopental. Using a sterile aspiration needle attached to a pre-heparinised syringe, approximately 12 ml of bone marrow aspirate was collected from the proximal humerus. The aspirates were immediately transported on ice to the laboratory and processed within the next two hours. Bone marrow mononuclear cells were separated by Ficoll (Histopaque-1077 density 1.077 g/ml, Sigma-Aldrich, St Louis, Missouri) density centrifugation at 4°C with 800 g for 35 minutes. Mononuclear cells (1×10^5 /cm²) were cultured in 25 cm² culture flasks containing 5 ml of low glucose Dulbecco’s modified eagle’s medium (DMEM, Sigma-Aldrich) supplemented with 10% foetal bovine serum, 2 mM L-glutamine, 10000 IU/ml penicillin and 100 µg/ml streptomycin at 37°c in the presence of CO₂. After four days, the non-adherent cells were removed by washing the culture dishes with Dulbecco’s phosphate buffered saline (DPBS, Sigma-Aldrich) and the culture medium was changed every two days. Adherent cells or BM-Mscs were cultured (passage 0) until they reached over 75% confluence. The cells were re-suspended by washing twice with DPBS and digested with 0.125% trypsin in ethylene diamine tetraacetic acid (EDTA) for two minutes. The enzyme was inactivated by 5 ml of foetal bovine serum in DMEM. The cell suspension was subsequently centrifuged at 4°C and 1000 rpm for 10 minutes and used for further passages. Passage 3 cells were seeded onto PRF and transplanted in osteochondral defects. Before transplantation they were characterised by flow cytometry and evaluation of cell surface markers (CD34, CD44, CD45 and CD105).

Preparation of PRF. Autologous PRF was prepared based on the method previously described by Dohan et al. 24 hours prior to surgery and creation of osteochondral defects, 20 ml of venous blood was withdrawn from the jugular vein of each dog and transferred into two sterile glass test tubes without any anticoagulant. The samples were immediately centrifuged at 3000 rpm (400 g) for ten minutes. The resultant PRF clot located in the middle layer of the test tube was removed and the red blood cells at the bottom and acellular plasma at the top of the tube were discarded. The PRF clots were transferred into 12 well flasks and 1 ml of DPBS was added to prevent drying and kept inside an incubator at 37°C for BM-MSC seeding later on.

Seeding of BM-MSCs onto PRF. On the day of the surgery, 1×10^6 cells of passage 3 BM-MSCs were added to PRF containing wells and incubated at 37°C for at least six hours before being transplanted into osteochondral defects during surgery (Fig. 1).
operation. The animal was placed in dorsal recumbency and under aseptic conditions. The medial approach to the stifle joint with lateral patellar luxation was used to access inside each of the right and left joints. The joint was fully flexed to access the weight-bearing areas of the femoral condyles. Osteochondral defects with a diameter of 6 mm and depth of 5 mm were created in the weight bearing area of each medial femoral condyle using a drill equipped with a 6 mm drill bit. Bleeding was observed in all the defects confirming the involvement of subchondral bone and the full thickness nature of the injury. The defects were thoroughly lavaged with normal saline solution (Shahid Ghazi Pharmaceutical Co., Tabriz, Iran). From a total of two defects created in each dog, one was press fitted with prF seeded with bM-Mscs (Fig. 1) and the other left empty as a control. After completion of the procedure, the patella was returned to its normal anatomic location and the joint capsule, subcutaneous tissues and skin sutured routinely to close the wound.

**Macroscopic evaluations.** Immediately after death, the International Cartilage Repair Society (ICRS) evaluation score (Table I) was used for macroscopic assessment of the repair tissue based on gross observation. Digital photographs of the defects were taken for documentation purposes. The assessment was blinded to treatment allocation.

**Histological (microscopic) evaluations.** Following macroscopic assessment, each femoral condyle was fixed in 10% buffered neutral formalin, decalcified and embedded in paraffin for routine histological sectioning. Sagittal sections (5 µm thick) were cut from the centre of each defect and stained with haematoxylin-eosin and safranin O and examined under a light microscope. Sections were blindly examined and scored according to the O’Driscoll histological grading scale (Table II).

**Statistical analysis.** Mann-Whitney U test was used to compare macroscopic and microscopic scores at different time points between the two treatment groups. A p-value < 0.05 was considered statistically significant. Graph Pad Prism 6 software package (Graph Pad Software Inc.) was used for data analysis.

### Results

#### Characteristics of BM-MSCs.

The criteria used for characterisation of BM-MSCs in this study were plastic adherence of cells which was observed during culture and expression of cell surface markers quantified by flow cytometry. The results of flow cytometric analysis indicated the positive expression of mesenchymal markers CD44 and CD105 by bM-Mscs while the non-mesenchymal markers CD34 and CD45 were negative.

#### Macroscopic findings.

All animals survived the surgery and recovered uneventfully. Signs of post-operative synovitis, joint infection, osteophyte formation and degenerative joint disease were not observed in any of the joints during the sampling procedure. The defects were readily identifiable from the surrounding normal cartilage in both treatment groups at all sampling times.

At four weeks after surgery, the full thickness defects of the BM-MSC-treated group were filled with a brightly red coloured repair tissue with remnants of PRF observed in the central areas of the repair tissue in two defects (Fig. 2). The repair tissue which had filled the defects of the control group had a darker red colour, and in the central areas, a slight depression was also evident. At 16 weeks after surgery, the reparative tissue filling the defects in both groups had an opaque white colour resembling the normal surrounding cartilage. The repair tissue had integrated well with the native cartilage at the edges of the defects in both treatment groups. The BM-MSC-treated defects were filled with an opaque white repair tissue very similar to the native cartilage and

---

**Table I.** International cartilage repair society macroscopic evaluation of cartilage repair.

| Categories                                      | Score |
|-------------------------------------------------|-------|
| Degree of defect repair                         |       |
| In level with surrounding cartilage             | 4     |
| 75% repair of defect depth                      | 3     |
| 50% repair of defect depth                      | 2     |
| 25% repair of defect depth                      | 1     |
| 0% repair of defect depth                       | 0     |
| Integration to border zone                      |       |
| Complete integration with surrounding cartilage | 4     |
| Demarcating border < 1 mm                       | 3     |
| ¼% of graft integrated, ¼ with a notable border > 1 mm width | 2    |
| ½ of graft integrated with surrounding cartilage, ½ with a notable border > 1 mm | 1     |
| From no contact to ¼ of graft integrated with surrounding cartilage | 0     |
| Macroscopic appearance                          |       |
| Intact smooth surface                           | 4     |
| Fibriiltated surface                            | 3     |
| Small, scattered fissures or cracks             | 2     |
| Several, small or few but large fissures        | 1     |
| Total degeneration of grafted area              | 0     |
| Overall repair assessment                       |       |
| Grade I: normal                                 | 12    |
| Grade II: nearly normal                         | 11-8  |
| Grade III: abnormal                             | 7-4   |
| Grade IV: severely abnormal                     | 3-1   |

---

California), therefore the number of defects which were treated by BM-MSCs and left empty as a control was four at each time point.

---

**Table II.** Histological grading scale.

| Grade     | Score |
|-----------|-------|
| Grade I   | 1     |
| Grade II  | 2     |
| Grade III | 3     |
| Grade IV  | 4     |

---

**Figures:**

1. A defect created in the central area of the repair tissue in two defects (Fig. 2).
2. The repair tissue which had filled the defects of the control group had a darker red colour, and in the central areas, a slight depression was also evident. At 16 weeks after surgery, the reparative tissue filling the defects in both groups had an opaque white colour resembling the normal surrounding cartilage. The repair tissue had integrated well with the native cartilage at the edges of the defects in both treatment groups. The BM-MSC-treated defects were filled with an opaque white repair tissue very similar to the native cartilage and
a slightly depressed central region 24 weeks post-operatively. The repair tissue filling the control defects at the same time had a dark red or purple colour with a larger and deeper central depression in comparison with the BM-MSC-treated defects. Although defect margins were still identifiable from the surrounding native cartilage in both groups, superior tissue integration of the repair tissue at the edges of the defect was observed in the BM-MSC-treated defects compared with the empty controls at 24 weeks post-operatively.

The results of macroscopic scoring of repair tissue indicated consistently higher scores in BM-MSC-treated defects in comparison with the controls at all sampling times (Fig. 3). The mean scores of BM-MSCs treated defects were significantly higher than the control defects at four and 24 weeks after surgery (9.25, SD 0.5 vs 7.25, SD 0.95 and 10, SD 0.81 vs 7.5, SD 0.57, respectively). The macroscopic scores of BM-MSCs treated defects at 16 and 24 weeks had increased compared with the four-week time point corresponding with the increased quality of reparative tissue, and its resemblance to native cartilage, which was observed macroscopically. The increase in macroscopic scores of the control defects at 16 weeks post-operatively in comparison with the four-week time point was also due to the improved quality of the repair tissue. There was a decrease in mean macroscopic scores of control defects at 24 weeks following surgery corresponding with the disintegration and loss of the quality of repair tissue which was observed macroscopically at this time point.

### Histological findings

The results of histological findings at four weeks after surgery indicated that defects treated with BM-MSCs were filled by fibrous tissue containing numerous fibroblasts and blood vessels (Fig. 4). Remnants of PRF were seen at the central portions of the defects as dark red stained areas. The repair tissue had integrated almost completely with the host cartilage at the edges of the defect and the surface of the repair tissue was smooth. The untreated control defects were also filled by a fibrous tissue. However, fewer fibroblasts were present, particularly near the surface of the defect and larger blood vessels were present. No obvious cartilaginous extracellular matrix was identified by safranin O staining in either group at four weeks after surgery. There was a decrease in mean macroscopic scores of control defects at 24 weeks following surgery corresponding with the disintegration and loss of the quality of repair tissue which was observed macroscopically at this time point.

### Table II. O’Driscoll histological cartilage repair scores

| Characteristics                                      | Score |
|------------------------------------------------------|-------|
| Nature of predominant tissue                         |       |
| Hyaline articular cartilage                           | 4     |
| Incompletely differentiated mesenchyme                 | 2     |
| Fibrous tissue or bone                                | 0     |
| Safranin-O staining of the matrix                      | 3     |
| Normal or nearly normal                               | 2     |
| Slight                                                 | 1     |
| None                                                  | 0     |
| Structural characteristics                            |       |
| Smooth and intact                                     | 3     |
| Superficial horizontal lamination                      | 2     |
| Fissures 25% to 100% of the thickness                 | 1     |
| Severe disruption including fibrillation              | 0     |
| Surface regularity                                     |       |
| Normal                                                 | 2     |
| Slight disruption including cysts                     | 1     |
| Severe disruption                                      | 0     |
| Thickness                                             |       |
| 100% of normal adjacent cartilage                     | 2     |
| 50% to 100% of normal cartilage                        | 1     |
| 0% to 50% of normal cartilage                          | 0     |
| Bonding to the adjacent cartilage                      |       |
| Bonded at both ends of graft                          | 2     |
| Bonded at one end or partially at both ends           | 1     |
| Not bonded                                            | 0     |
| Freedom from degenerative changes in adjacent cartilage|       |
| Normal cellularity, no clusters, normal staining      | 3     |
| Normal cellularity, mild clusters, slight staining     | 2     |
| Mild or moderate hypocellularity, slight staining      | 1     |
| Severe hypocellularity, poor or no staining           | 0     |
| Total                                                 | 24    |
deeper parts of the defect towards the surface. They were stained positively with safranin O indicating the presence of cartilaginous extracellular matrix in the regenerated tissue. These findings were also observed in BM-MSCs treated defects at 24 weeks, although the centre of the defects was filled by fibrous tissue (Fig. 6). Intense clustering of the chondrocytes was a constant feature observed at the native edges of the defect in the untreated control group at 16 and 24 weeks following surgery (Figs 5 and 6).

The histological observations described above are also reflected in terms of histological scoring of the repair tissue. The mean histological scores of BM-MSC-treated group were consistently higher than the untreated controls (Fig. 7) although statistically significant difference between the two groups was only observed at 16 weeks after surgery (16.5, sd 4.04 vs 11, sd 1.15, respectively).

Discussion
This study has successfully demonstrated the feasibility of using a combination of stem cells originating from bone marrow with a type of platelet concentrate as a novel strategy in cartilage repair. The quality of repair tissue observed in osteochondral defects treated by this combined method of therapy was superior to untreated defects in terms of both macroscopic and histological criteria, and even partial articular cartilage regeneration was evident. The suitability of PRF as an autologous biomaterial scaffold for implantation of stem cells in cartilage defects was also demonstrated in this study.

Fig. 3
Mean International Cartilage Repair Society macroscopic scores for control and stem cell treated (bone-marrow derived mesenchymal stem cell (BM-MSC)) groups at four, 16 and 24 weeks after surgery. Error bars indicate standard deviation and the p-values (Mann Whitney U test) represent the statistical differences between the two treatment groups.

Fig. 4
Histological appearance of defects in the condylar region at four weeks after surgery. Control as well as stem cell treated (bone-marrow derived mesenchymal stem cell) defects are represented. Magnified views of the boxes are presented in the middle and right side. SafraninO staining; original magnification 40x (left side) and 100x (middle and right side).
The ICRS macroscopic grading was used in this study in order to grade the repair tissue. Macroscopic evaluation is a frequent feature of animal studies in the field of cartilage repair because the whole joint is accessible, and this method provides the first impressions of the quality of repair tissue. The ICRS macroscopic grading system is validated and reliable. The benchmark for evaluation of the success of various cartilage repair procedures is Histological
canine species. A critical size cartilage defect is defined as the minimum defect dimension in diameter that the animal is incapable of repairing without intervention. For the canine species, the critical size of the defect is 4 mm, although defects of larger than 5 mm are generally considered critical and the depth of the surgically created defect ranges from 3 mm to 12 mm depending on the type of defect, i.e., chondral or osteochondral.

The ultimate goal of all cartilage repair techniques is to produce a repair tissue with similar structural, biochemical and biomechanical characteristics to normal hyaline cartilage. Implantation of BM-MSCs in osteochondral defects is an exogenous form of cell therapy. BM-MSCs have the potential to differentiate into chondrocytes and regenerate articular cartilage. Growth factors, particularly TGF-β family, are strong inducers of chondrogenesis. In addition, homeostasis and the repair of articular cartilage is regulated by a number of growth factors including: TGF-β, fibroblast growth factor (FGF), insulin-like growth factor 1 (IGF-1) and platelet-derived growth factor (PDGF). Considered as a natural bioscaffold; PRF is a rich source of these growth factors. PRF is termed as a second-generation platelet concentrate to distinguish it from platelet rich plasma (PRP), which is classified as first generation platelet concentrate. All platelet concentrates have evolved from fibrin sealants or fibrin glues which are prepared from whole plasma and essentially contain fibrinogen. The addition of calcium chloride or bovine thrombin to fibrin sealants at the time of application results in the formation of fibrin clot. Despite having a similar origin, there are numerous differences between PRF and PRP, which are briefly summarised in Table III. PRF does not dissolve quickly after application because of its unique structural properties and the solid consistency of fibrin which results in slow release of growth factors over an extended period of time. Previous studies have indicated that numerous growth factors are involved in the process of chondrogenesis, and the use of multiple growth factors could better stimulate cartilage regeneration as opposed to a single factor and application. PRF fulfils this concept of multiple growth factor delivery. Based on the above assumptions, we hypothesised that the combined use of BM-MSCs and PRF could have regenerative effects on articular cartilage.

To the best of our knowledge, this is the first study to examine the effect of BM-MSCs transplanted onto PRF in cartilage repair and regeneration. Studies concerning tissues other than articular cartilage have shown that the combination of MSCs and PRF has resulted in significantly more tissue repair and regeneration compared with either MSCs or PRF therapy alone or no treatment. Chen et al. have investigated the effect of PRF on proliferation and osteogenic differentiation of canine BM-MSCs. It was found that the proliferation of stem cells was stimulated, but PRF alone had no effect on their osteogenic differentiation. The authors concluded that the proliferative effects were likely due to the release of growth factors from PRF. In a similar in vitro study, Dohan Ehrenfest et al. and colleagues demonstrated that PRF had a significant stimulatory effect on both proliferation and differentiation of human oral bone MSCs. As stated previously, the combined use of stem cells and PRF has not been reported in the literature, but the application of stem cells plus PRP for cartilage repair has been reported in three studies. The clinical use of autologous culture expanded BM-MSCs transplanted onto platelet rich fibrin
glue was first reported by Haleem et al.\textsuperscript{50} Significant functional and diagnostic imaging improvements were observed in human patients with second look arthroscopy indicating the presence of nearly normal hyaline cartilage. It must be noted that despite the use of the term PRF by the authors, the platelet concentrate used by Haleem et al was actually PRP. In another study conducted by Xie et al\textsuperscript{51} on rabbits, treatment of full thickness cartilage defects of rabbits with the formation of hyaline cartilage and significantly higher histological scores at six and 12 weeks after surgery. The authors concluded that PRF may be a suitable scaffold for cell based cartilage repair as it is capable of releasing growth factors and inducing the differentiation of stem cells to chondrocytes. Application of synovial membrane derived MSCs and PRF also resulted in successful treatment of experimental cartilage defects of rabbits with the formation of hyaline cartilage and significantly higher histological scores 24 weeks after surgery.\textsuperscript{52} These studies indicate that PRF is capable of creating a beneficial environment to promote in vivo proliferation and differentiation of stem cells. PRF, used in our study, could also create this favourable environment as it also contains growth factors and releases them in a longer period of time compared with PRP.

This study does have limitations. Collagen type characterisation by immunohistochemical staining methods and stiffness tests to determine the biomechanical properties of the repair tissue were not carried out. Furthermore, it was not possible to extend the study period to evaluate the repair tissue over an even longer period of time, for example up to one year after surgery. The main objective of the present study was to evaluate the feasibility of using the combination of BM-MSCs and PRF as a novel treatment method in cartilage repair and regeneration. To accomplish this, osteochondral defects treated with BM-MSCs seeded on PRF were compared with the empty control defects. Therefore, it was not possible to compare the regenerative effects of PRF or BM-MSCs alone with that of the combination of BM-MSCs and PRF. This could also be considered as another limitation of this study. The main factor for the above limitations was financial constraints. Above all, it must be noted that the stem cell seeded PRF was press fitted inside relatively deep osteochondral defects in the present study. This technique could be used in a similar fashion for treatment of large osteochondral defects in a clinical setting but it is not clear whether the stem cell seeded PRF would remain in place inside shallower partial thickness or full thickness cartilage defects without using any patches or membranes. The treatment of partial thickness or full thickness cartilage defects using combination of MSCs and PRF requires further investigations.

Our findings have demonstrated that transplantation of autologous BM-MSCs onto PRF is a promising, novel, method of osteochondral repair and articular cartilage regeneration within the context of cell therapy. Further studies are required in this subject area. The use of PRF creates a suitable environment for proliferation and differentiation of BM-MSCs into chondrocytes with the appearance of a hyaline like tissue with improved macroscopic and histological characteristics.

**References**

1. Krych AJ, Gobbi A, Lattemann C, Nakamura N. Articular cartilage solutions for the knee: present challenges and future direction. JISAKOS; 2016;0:1-12.
2. Bernhard JC, Yunjak-Novakovic G. Should we use cells, biomaterials, or tissue engineering for cartilage regeneration? Stem Cell Res Ther 2016;7:56.
3. Madeira C, Santhagunam A, Salgueiro JB, Cabral JM. Advanced cell therapies for articular cartilage regeneration. Trends Biotechnol 2015;33:35-42.
4. Hunziker EB, Lippuner K, Keel MJB, Shintani N. An educational review of cartilage repair: precepts & practice--myths & misconceptions--progress & prospects. Osteoarthritis Cartilage 2015;23:334-350.
5. Myers KR, Spagnione NA, Grande DA. Trends in biological joint resurfacing. Bone Joint Res 2012;2:195-199.
6. Thiode RM, Lu Y, Markel MD. A review of the treatment methods for cartilage defects. Vet Comp Orthop Traumatol 2012;25:263-272.
7. Shafiee A, Kabiri M, Langroudi L, et al. Evaluation and comparison of the in vitro characteristics and chondrogenic capacity of four adult stem/progenitor cells for cartilage cell-based repair. J Biomed Mater Res A 2015;104:600-610.
8. Baghaban Esalamnejad M, Malakooty Poor E. Mesenchymal stem cells as a potent cell source for articular cartilage regeneration. World J Stem Cells 2014;6:344-354.
9. Koga H, Engbretsen L, Brinchmann JE, et al. Mesenchymal stem cell-based therapy for cartilage repair: a review. Knee Surg Sports Traumatol Arthrosc 2009;17:1289-1297.
10. McCarty R, Leavesley DJ, Simmons P. Application of Mesenchymal Stem Cells for repair and regeneration of cartilage and bone. Australian Biochemist 2005;36:7-10.
11. Wakitani S, Goto T, Pineda SJ, et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. J Bone Joint Surg (Am) 1984;76-A:579-592.
12. Bomes TD, Adesida AB, Jomha NM. Mesenchymal stem cells in the treatment of traumatic articular cartilage defects: a comprehensive review. Arthritis Res Ther 2014;16:432.
13. Redman SN, Oldfield SF, Archer CW. Current strategies for articular cartilage repair. Eur Cell Mater 2005;9:23-32.
14. Orth P, Rey-Rico A, Venkatesan JK, et al. Current perspectives in stem cell research for knee cartilage repair. Stem Cells Cloning 2014;7:1-17.
15. Kang YH, Jeon SH, Park JY, et al. Platelet-rich fibrin is a Bio scaffold and reservoir of growth factors for tissue regeneration. Tissue Eng Part A 2011;17:349-359.

16. Chatterjee A, Agarwal P, Subbaiah SK. Platelet rich fibrin: an autologous bioactive membrane. Apollo Medicine 2014;11:24-26.

17. He L, Lin Y, Hu X, et al. A comparative study of platelet-rich fibrin (PRF) and platelet-rich plasma (PRP) on the effect of proliferation and differentiation of rat osteoblasts in vitro. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:707-713.

18. Choukroun J, Braccini F, Dias A, et al. Influence of platelet-rich fibrin (PRF) on proliferation of human periosteocytes and tympanic keratinocytes: A new opportunity in facial reconstructive (Coleman's technique) and tympanoplasty. Rev Laryngol Otol Rhinol (Bord) 2007;128:27-32.

19. Dohan Ehrenfest DM, Dass A, Odin G, et al. In vitro effects of Choukroun’s PRF (platelet-rich fibrin) on human gingival fibroblasts, dental prekeratinocytes, preadipocytes, and maxillofacial osteoblasts in primary cultures. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:341-352.

20. Dohan Ehrenfest DM, Doglioti P, de Peppo GM, et al. Choukroun's platelet-rich fibrin (PRF) stimulates in vitro proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. Arch Oral Biol 2010;55:185-194.

21. Honda H, Tamai N, Naka N, et al. Bone tissue engineering with bone marrow-derived stromal cells integrated with concentrated growth factor in Rattus norvegicus calvaria defect model. J Artif Organs 2013;16:305-315.

22. Zhao YH, Zhang M, Liu NX, et al. The combined use of cell sheet fragments of periodontal ligament stem cells and platelet-rich fibrin granules for avulsed tooth reimplantation. Biomaterials 2013;34:5506-5520.

23. Chen YJ, Zhao YH, Zhao YJ, et al. Potential dental pulp revascularization and odonto-/osteogenic capacity of a novel transplant combined with dental pulp stem cells and platelet-rich fibrin. Cell Tissue Res 2015;361:439-455.

24. Ji B, Sheng L, Chen G, et al. The combination use of platelet-rich fibrin and treated dentin matrix for tooth root regeneration by cell homing. Tissue Eng Part A 2015;21:26-34.

25. Sun CK, Zhen YL, Leu S, et al. Direct implantation versus platelet-rich fibrin-embedded adipose-derived mesenchymal stem cells in treating rat acute myocardial infarction. Int J Cardiol 2014;172:410-423.

26. Chen YL, Sun CK, Tsai TH, et al. Adipose-derived mesenchymal stem cells embedded in platelet- rich fibrin scaffolds promote angiogenesis, preserve heart function, and reduce left ventricular remodeling in rat acute myocardial infarction. Am J Transl Res 2015;7:781-803.

27. Wang Z, Weng Y, Lu S, et al. Osteoblastic mesenchymal stem cell sheet combined with Choukroun platelet-rich fibrin induces bone formation at an ectopic site. J Biomed Mater Res B Appl Biomater 2015;103:1204-1216.

28. Liu B, Tan XY, Liu YP, et al. The adjuvant use of stromal vascular fraction and platelet-rich fibrin for autologous adipose tissue transplantation. Tissue Eng Part C Methods 2012;18:19-14.

29. Kazemi D, Fakhriou A, Dizaji VM, Alisahi MK. Effect of autologous platelet-rich fibrin on the healing of experimental articular cartilage defects of the knee in an animal model. Biomed Res 2014;2014:486438.

30. Takemitsu H, Zhao D, Yamamoto I, et al. Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. BMC Vet Res 2012;8:150.

31. Tharasanit T, Phuthikant N, Wangdee C, et al. Differentiation potentials of canine bone marrow mesenchymal stem cells. Thai J Vet Med 2011;41:79-86.

32. Kang MH, Park HK. Evaluation of adverse reactions in dogs following intravenous mesenchymal stem cell transplantation. Vet Cardiol 2014;8:16.

33. Dohan DM, Choukroun J, Dass A, et al. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. J Oral Biol Craniofac Res 2011;1:5-8.

34. Britberg M, Peterson L. Introduction to an articular cartilage classification. ICRS Newsletter 1998;1:5-8.

35. O’Driscoll SW, Keeley FW, Salter RB. The chondrogenic potential of free autogenous periosteal grafts for biological resurfacing of major full-thickness defects in joint surfaces under the influence of continuous passive motion. An experimental investigation in the rabbit. J Bone Joint Surg [Am] 1986;68-A:1017-1035.

36. Goebel L, Orth P, Muller A, et al. Experimental scoring systems for macroscopic articular cartilage repair correlate with the MCARD score assessed by a high-field MRI at 8 T—comparative evaluation of five macroscopic scoring systems in a large animal cartilage defect model. Osteoarthritis Cartilage 2012;20:1046-1055.

37. Rutgers M, van Pelt MJ, Dhert WJ, et al. Evaluation of histological scoring systems for tissue-engineered, repaired and osteoarthritis cartilage. Osteoarthritis Cartilage 2010;18:12-23.

38. Hoemann C, Kandel R, Roberts S, et al. International Cartilage Repair Society (ICRS) recommended guidelines for histological endpoints for cartilage repair studies in animal models and clinical trials. Cartilage 2011;2:153-172.

39. Reinholz GG, Lu L, Saris DB, et al. Animal models for cartilage reconstruction. Biomaterials 2004;25:1511-1521.

40. Ahern BJ, Parvizi J, Boston R, Schaer TP. Preclinical animal models in single site cartilage defect testing: a systematic review. Osteoarthritis Cartilage 2009;17:705-713.

41. Chu CR, Szczytko M, Bruno S. Animal models for cartilage regeneration and repair. Tissue Eng Part B Rev 2010;16:105-115.

42. Cook JL, Hung CT, Kuroki K, et al. Animal models of cartilage repair. Bone Joint Res 2014;2:89-94.

43. Dohan Ehrenfest DM, Lemo N, Jingo R, Sammartino G. Selecting a relevant animal model for testing the in vivo effects of Choukroun’s platelet-rich fibrin (PRF): rabbit tricks and traps. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010;110:413-416.

44. Volk SW, Theoret C. Translating stem cell therapies: the role of companion animals in regenerative medicine. Wound Repair Regen 2013;21:382-394.

45. Kim SH, Min BH. A new era of cartilage repair using cell therapy and tissue engineering: turning current clinical limitations into new ideas. TERM 2012;9:240-248.

46. Lam J, Lu S, Kasper FK, Mikos AG. Strategies for controlled delivery of biologics for cartilage repair. Adv Drug Deliv Rev 2015;84:123-134.

47. Dohan Ehrenfest DM, de Peppo GM, Doglioti P, Sammartino G. Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors 2008;27:83-69.

48. Chen KS, Chien KC, Huang YS, et al. Proliferative effect of platelet-rich fibrin on canine bone marrow-derived stromal cells. Taiwan Veterinary Journal 2014;40:151-161.

49. Dohan Ehrenfest DM, Doglioti P, de Peppo GM, et al. Choukroun’s platelet-rich fibrin (PRF) stimulates in vivo proliferation and differentiation of human oral bone mesenchymal stem cell in a dose-dependent way. Arch Oral Biol 2010;55:185-194.

50. Haleem AM, Singergy AA, Sabry D, et al. The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects a pilot study and preliminary results. Cartilage 2010;1:253-261.

51. Xie X, Wang Y, Zhao C, et al. Comparative evaluation of MSCs from bone marrow and adipose tissue seeded in PRF-derived scaffold for cartilage regeneration. Biomaterials 2012;33:7008-7018.

52. Lee JC, Min HJ, Park HJ, et al. Synovial membrane-derived mesenchymal stem cells supported by platelet-rich plasma can repair osteochondral defects in a rabbit model. Arthroscopy 2013;29:1034-1046.

Funding Statement
This work was financially supported by Tabriz Branch, Islamic Azad University (research project contract number 2-17-5-16154).

Author Contribution
D. Kazemi: Conceived and designed the study, carried out the animal experiments, acquired and analysed data and drafted the manuscript.
K. Shams Asenjan: Conducted the laboratory experiments and participated in data acquisition and drafting of the manuscript.
N. Dehdilani: Conducted the laboratory experiments and participated in data acquisition and drafting of the manuscript.
H. Pena: Conducted the laboratory experiments and participated in data acquisition and drafting of the manuscript.

ICMJE Conflicts of Interest
None declared

© 2017 Kazemi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution licence (CC-BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, but not for commercial gain, provided the original author and source are credited.